News
Lilly Drops $2. 3 Billion On Cambridge Cancer Upstart In Myelofibrosis Power Play
1+ day, 17+ hour ago (815+ words) Eli Lilly agreed to acquire Ajax Therapeutics for up to $2. 3 B to gain AJ111095, a Type II JAK2 inhibitor in Phase 1 for myelofibrosis; data due in 2026. Lilly Drops $2. 3 Billion On Cambridge Cancer Upstart In Myelofibrosis Power Play Eli Lilly is laying down…...
Hemab Files For $212 M IPO, Eyes Nasdaq Debut
1+ day, 11+ hour ago (196+ words) According to Bloomberg, the filing lists the Novo Nordisk Foundation among Hemab's biggest investors and shows the company marketing 11. 8 million shares at $16 to $18 apiece. Bloomberg also notes that the top of that range would put Hemab's market value at about…...